Managing SLS: Standard of Care and Treatments
Last updated:
Managing Sjögren-Larsson syndrome (SLS) requires a multidisciplinary approach focusing on symptom relief. Standard care includes daily keratolytics and retinoids for severe skin scaling, physical therapy and baclofen for muscle spasticity, and a specialized LCFA-restricted diet.
Key Takeaways
- • A multidisciplinary team including neurologists, dermatologists, and physical therapists is essential for managing Sjögren-Larsson syndrome.
- • Daily intensive moisturizers, keratolytics, and medications like acitretin or dupilumab are used to manage severe skin scaling and intractable itching.
- • Physical therapy, orthotics, and muscle relaxers such as baclofen help reduce muscle spasticity and improve patient mobility.
- • A specialized diet restricted in long-chain fatty acids (LCFA) can significantly reduce toxic fatty aldehyde buildup and improve skin symptoms.
- • Emerging research is exploring gene therapy and aldehyde scavengers as potential future treatments targeting the root cause of SLS.
Managing Sjögren-Larsson Syndrome (SLS) requires a coordinated, multidisciplinary approach [1]. This means your child’s care team will likely include a variety of specialists—including neurologists, dermatologists, and physical therapists—all working together to manage symptoms [1][2]. While there is currently no cure for SLS, many effective treatments exist to improve comfort, mobility, and overall quality of life [3][4].
Dermatological Care: Managing Skin and Itching
The goal of skin care in SLS is to soften the skin, reduce scaling, and soothe the intense itching (pruritus) that is a hallmark of the condition [4].
- Topical Treatments: Daily use of intensive moisturizers and keratolytics (substances that help break down the outer layer of skin) is essential for managing ichthyosis [4][2].
- Systemic Medications: A low-dose retinoid called acitretin has been shown to significantly decrease skin thickness and scaling, leading to a better quality of life for both children and their caregivers [4].
- Targeting the Itch: For severe, “intractable” itching that doesn’t respond to standard lotions, a biologic medication called dupilumab has shown promising results in providing long-lasting relief and improving sleep [5].
Neurological & Motor Care: Improving Mobility
Addressing muscle stiffness (spasticity) is key to helping your child move more easily and preventing permanent muscle shortening (contractures) [6][7].
- Physical Therapy & Support: Regular physical therapy and the use of orthotics (such as Ankle-Foot Orthoses or AFOs) are vital for maintaining flexibility and improving independence [1][8].
- Spasticity Medications: Baclofen is a common medication used to relax muscles [9]. It can be taken orally, or in more severe cases, delivered directly to the spinal fluid via an intrathecal baclofen pump [10].
- Surgical Options: If spasticity is severe or has caused fixed deformities, procedures like Selective Dorsal Rhizotomy (SDR) or orthopedic surgeries may be considered to help loosen the muscles and improve walking [11][12].
The Role of Diet and Nutrition
In some metabolic disorders, specialized diets are a standard part of treatment. For SLS, a recognized therapeutic option is a diet restricted in long-chain fatty acids (LCFA) and supplemented with medium-chain triglycerides (MCT) [13][9].
While the body does produce some of these toxic fats internally (endogenous metabolism), reducing the external load of these fats through diet can be highly beneficial. While an LCFA-restricted/MCT-supplemented diet typically does not reverse neurological symptoms, it is frequently used to significantly reduce the buildup of fatty aldehydes. For many patients, this can dramatically improve severe skin scaling and intractable itching [9]. It is highly recommended to discuss this dietary approach with a specialized metabolic dietitian.
Research and Future Directions
Scientists are currently investigating new ways to treat the root cause of SLS. These experimental approaches include:
- Aldehyde Scavengers (e.g., ADX-102): Drugs designed to “trap” and neutralize the toxic fatty aldehydes before they can damage cells [9][14].
- Gene Therapy: Research into ways to provide cells with a functional copy of the ALDH3A2 gene [9].
- PPAR-α Agonists: Medications that may help stimulate whatever enzyme activity is left in the body [9].
While these are not yet standard treatments, they represent an active area of hope and research for the future [9].
To learn about who exactly will prescribe and manage these treatments, see Building Your Child’s Care Team for SLS.
Frequently Asked Questions
What are the best treatments for the skin issues in Sjögren-Larsson syndrome?
How is muscle stiffness or spasticity managed in children with SLS?
Does diet play a role in treating Sjögren-Larsson syndrome?
Are there any experimental or future treatments for SLS?
Questions for Your Doctor
- • Which topical agents or keratolytics do you recommend for daily skin maintenance to reduce scaling?
- • Is my child a candidate for oral baclofen, or should we be considering an intrathecal baclofen pump for more direct relief of leg stiffness?
- • How can we best coordinate care between our neurologist, dermatologist, and physical therapist?
- • If the itching becomes severe, can we discuss the potential use of dupilumab as a targeted treatment option?
- • What is the current status of clinical trials for aldehyde-trapping drugs like ADX-102, and is my child eligible?
Questions for You
- • Which symptoms are currently most impacting your child's daily comfort and mobility?
- • Have you noticed any changes in how your child’s skin responds to different moisturizers or environmental factors?
- • What are your primary goals for physical therapy in the coming months (e.g., walking with a walker, improved sitting balance)?
- • How much is itching or skin discomfort affecting your child’s ability to sleep or participate in school?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Infantile onset ascending hereditary spastic paralysis.
Eltoum A, O'Rourke D, Sharif F
BMJ case reports 2022; (15(1)) doi:10.1136/bcr-2020-240941.
PMID: 35039335 - 2
Sjögren-Larsson Syndrome: A Rare Presentation With Developmental Delay.
J SK, Waheed MD, Batool S, et al.
Cureus 2023; (15(2)):e35159 doi:10.7759/cureus.35159.
PMID: 36950004 - 3
Sjögren-Larsson syndrome: a rare disease of the skin and central nervous system.
Roy U, Das U, Pandit A, Debnath A
BMJ case reports 2016; (2016()):10.1136/bcr-2016-215110.
PMID: 27095813 - 4
Clinical and molecular characterization and response to acitretin in three families with Sjögren-Larsson syndrome.
Vural S, Vural A, Akçimen F, et al.
International journal of dermatology 2018; (57(7)):843-848 doi:10.1111/ijd.14013.
PMID: 29704247 - 5
Dupilumab Reduces Pruritus in Twins With Sjögren-Larsson Syndrome.
Gallagher K, Yousif R, Hummel K, Paller AS
Pediatric dermatology 2025; doi:10.1111/pde.70073.
PMID: 41046861 - 6
Genetic assessment of ten Egyptian patients with Sjögren-Larsson syndrome: expanding the clinical spectrum and reporting a novel ALDH3A2 mutation.
Amr K, El-Bassyouni HT, Ismail S, et al.
Archives of dermatological research 2019; (311(9)):721-730 doi:10.1007/s00403-019-01953-6.
PMID: 31388754 - 7
A Neurodegenerative Phenotype Associated With Sjögren-Larsson Syndrome.
Warrack S, Love T, Rizzo WB
Journal of child neurology 2021; (36(11)):1011-1016 doi:10.1177/08830738211029390.
PMID: 34315315 - 8
Small touches to big walks -the impact of rehabilitation on Sjögren-Larsson syndrome: A case report.
Yolcu G, Huseynli L, Kenis-Coskun O, Karadag-Saygi E
Journal of pediatric rehabilitation medicine 2022; (15(3)):533-537 doi:10.3233/PRM-201521.
PMID: 35871376 - 9
Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.
Rizzo WB
Expert opinion on orphan drugs 2016; (4(4)):395-406 doi:10.1517/21678707.2016.1154453.
PMID: 27547594 - 10
Intrathecal Baclofen Therapy for the Treatment of Spasticity in Sjögren-Larsson Syndrome.
Hidalgo ET, Orillac C, Hersh A, et al.
Journal of child neurology 2017; (32(1)):100-103 doi:10.1177/0883073816671440.
PMID: 28257279 - 11
Muscle Tone Assessment under General Anesthesia for Sjögren-Larsson Syndrome and Spasticity.
Georgoulis G, Dinopoulos A, Gkliatis E
Pediatric neurosurgery 2021; (56(2)):163-165 doi:10.1159/000514329.
PMID: 33725695 - 12
Selective dorsal rhizotomy for spastic diplegia secondary to stroke in an adult patient.
Eppinger MA, Berman CM, Mazzola CA
Surgical neurology international 2015; (6()):111 doi:10.4103/2152-7806.159382.
PMID: 26167363 - 13
Sjogren-Larsson Syndrome: Mechanisms and Management.
Bindu PS
The application of clinical genetics 2020; (13()):13-24 doi:10.2147/TACG.S193969.
PMID: 32021380 - 14
Sjögren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents.
Rizzo WB, S'aulis D, Dorwart E, Bailey Z
Molecular genetics and metabolism reports 2022; (30()):100839 doi:10.1016/j.ymgmr.2021.100839.
PMID: 35242571
This page provides general information on treatment options for Sjögren-Larsson syndrome. Always consult your child's multidisciplinary care team for personalized medical advice and symptom management.
Stay up to date
Get notified when new research about Sjögren-Larsson syndrome is published.
No spam. Unsubscribe anytime.